Equine Mesenchymal Stem/Stromal Cells Freeze-Dried Secretome (Lyosecretome) for the Treatment of Musculoskeletal Diseases : Production Process Validation and Batch Release Test for Clinical Use
In the last decades, it has been demonstrated that the regenerative therapeutic efficacy of mesenchymal stromal cells is primarily due to the secretion of soluble factors and extracellular vesicles, collectively known as secretome. In this context, our work described the preparation and characterization of a freeze-dried secretome (Lyosecretome) from adipose tissue-derived mesenchymal stromal cells for the therapy of equine musculoskeletal disorder. An intraarticular injectable pharmaceutical powder has been formulated, and the technological process has been validated in an authorized facility for veterinary clinical-use medicinal production. Critical parameters for quality control and batch release have been identified regarding (i) physicochemical properties; (ii) extracellular vesicle morphology, size distribution, and surface biomarker; (iii) protein and lipid content; (iv) requirements for injectable pharmaceutical dosage forms such as sterility, bacterial endotoxin, and Mycoplasma; and (v) in vitro potency tests, as anti-elastase activity and proliferative activity on musculoskeletal cell lines (tenocytes and chondrocytes) and mesenchymal stromal cells. Finally, proteins putatively responsible for the biological effects have been identified by Lyosecretome proteomic investigation: IL10RA, MXRA5, RARRES2, and ANXA1 modulate the inflammatory process RARRES2, NOD1, SERPINE1, and SERPINB9 with antibacterial activity. The work provides a proof-of-concept for the manufacturing of clinical-grade equine freeze-dried secretome, and prototypes are now available for safety and efficacy clinical trials in the treatment of equine musculoskeletal diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Pharmaceuticals (Basel, Switzerland) - 14(2021), 6 vom: 10. Juni |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mocchi, Michela [VerfasserIn] |
---|
Links: |
---|
Themen: |
Equine |
---|
Anmerkungen: |
Date Revised 14.07.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/ph14060553 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327473444 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327473444 | ||
003 | DE-627 | ||
005 | 20231225200848.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ph14060553 |2 doi | |
028 | 5 | 2 | |a pubmed24n1091.xml |
035 | |a (DE-627)NLM327473444 | ||
035 | |a (NLM)34200627 | ||
035 | |a (PII)553 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mocchi, Michela |e verfasserin |4 aut | |
245 | 1 | 0 | |a Equine Mesenchymal Stem/Stromal Cells Freeze-Dried Secretome (Lyosecretome) for the Treatment of Musculoskeletal Diseases |b Production Process Validation and Batch Release Test for Clinical Use |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 14.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a In the last decades, it has been demonstrated that the regenerative therapeutic efficacy of mesenchymal stromal cells is primarily due to the secretion of soluble factors and extracellular vesicles, collectively known as secretome. In this context, our work described the preparation and characterization of a freeze-dried secretome (Lyosecretome) from adipose tissue-derived mesenchymal stromal cells for the therapy of equine musculoskeletal disorder. An intraarticular injectable pharmaceutical powder has been formulated, and the technological process has been validated in an authorized facility for veterinary clinical-use medicinal production. Critical parameters for quality control and batch release have been identified regarding (i) physicochemical properties; (ii) extracellular vesicle morphology, size distribution, and surface biomarker; (iii) protein and lipid content; (iv) requirements for injectable pharmaceutical dosage forms such as sterility, bacterial endotoxin, and Mycoplasma; and (v) in vitro potency tests, as anti-elastase activity and proliferative activity on musculoskeletal cell lines (tenocytes and chondrocytes) and mesenchymal stromal cells. Finally, proteins putatively responsible for the biological effects have been identified by Lyosecretome proteomic investigation: IL10RA, MXRA5, RARRES2, and ANXA1 modulate the inflammatory process RARRES2, NOD1, SERPINE1, and SERPINB9 with antibacterial activity. The work provides a proof-of-concept for the manufacturing of clinical-grade equine freeze-dried secretome, and prototypes are now available for safety and efficacy clinical trials in the treatment of equine musculoskeletal diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a equine | |
650 | 4 | |a mesenchymal stem cells | |
650 | 4 | |a musculoskeletal disorders | |
650 | 4 | |a regenerative medicine | |
650 | 4 | |a secretome | |
700 | 1 | |a Grolli, Stefano |e verfasserin |4 aut | |
700 | 1 | |a Dotti, Silvia |e verfasserin |4 aut | |
700 | 1 | |a Di Silvestre, Dario |e verfasserin |4 aut | |
700 | 1 | |a Villa, Riccardo |e verfasserin |4 aut | |
700 | 1 | |a Berni, Priscilla |e verfasserin |4 aut | |
700 | 1 | |a Conti, Virna |e verfasserin |4 aut | |
700 | 1 | |a Passignani, Giulia |e verfasserin |4 aut | |
700 | 1 | |a Brambilla, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Bue, Maurizio Del |e verfasserin |4 aut | |
700 | 1 | |a Catenacci, Laura |e verfasserin |4 aut | |
700 | 1 | |a Sorrenti, Milena |e verfasserin |4 aut | |
700 | 1 | |a Segale, Lorena |e verfasserin |4 aut | |
700 | 1 | |a Bari, Elia |e verfasserin |4 aut | |
700 | 1 | |a Mauri, Pierluigi |e verfasserin |4 aut | |
700 | 1 | |a Torre, Maria Luisa |e verfasserin |4 aut | |
700 | 1 | |a Perteghella, Sara |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceuticals (Basel, Switzerland) |d 2009 |g 14(2021), 6 vom: 10. Juni |w (DE-627)NLM199619514 |x 1424-8247 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2021 |g number:6 |g day:10 |g month:06 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/ph14060553 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2021 |e 6 |b 10 |c 06 |